chr2-21006189-T-C

Variant summary

Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2PP3_StrongPP5

The NM_000384.3(APOB):​c.10679A>G​(p.Tyr3560Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,754 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: not found (cov: 33)
Exomes 𝑓: 6.8e-7 ( 0 hom. )

Consequence

APOB
NM_000384.3 missense

Scores

5
9
2

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:6U:4

Conservation

PhyloP100: 2.63
Variant links:
Genes affected
APOB (HGNC:603): (apolipoprotein B) This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins (LDL), and is the ligand for the LDL receptor. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Dec 2019]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_pathogenic. Variant got 7 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.949
PP5
Variant 2-21006189-T-C is Pathogenic according to our data. Variant chr2-21006189-T-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 265892.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=6, Uncertain_significance=4, Pathogenic=1}. Variant chr2-21006189-T-C is described in Lovd as [Likely_pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
APOBNM_000384.3 linkuse as main transcriptc.10679A>G p.Tyr3560Cys missense_variant 26/29 ENST00000233242.5 NP_000375.3

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
APOBENST00000233242.5 linkuse as main transcriptc.10679A>G p.Tyr3560Cys missense_variant 26/291 NM_000384.3 ENSP00000233242 P1

Frequencies

GnomAD3 genomes
Cov.:
33
GnomAD3 exomes
AF:
0.0000120
AC:
3
AN:
250954
Hom.:
0
AF XY:
0.00000737
AC XY:
1
AN XY:
135602
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000869
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
6.84e-7
AC:
1
AN:
1461754
Hom.:
0
Cov.:
36
AF XY:
0.00000138
AC XY:
1
AN XY:
727176
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
Cov.:
33
Alfa
AF:
0.0000329
Hom.:
0
Bravo
AF:
0.0000302
ExAC
AF:
0.00000824
AC:
1

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:6Uncertain:4
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Hypercholesterolemia, autosomal dominant, type B Pathogenic:3
Likely pathogenic, criteria provided, single submitterclinical testingLaboratory of molecular diagnosis of dyslipidemias, Università egli studi di Napoli Federico IIMay 24, 2021- -
Likely pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpNov 14, 2023Variant summary: APOB c.10679A>G (p.Tyr3560Cys) results in a non-conservative amino acid change in the encoded protein sequence. Three of three in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 250954 control chromosomes (gnomAD). c.10679A>G has been reported in the literature in multiple individuals affected with Familial Defective Apolipoprotein B/Familial Hypercholesterolaemia (example, Medeiros_2010, Liyange_2008, Vaca_2011, Medeiros_2014, Futema_2021). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 18325181, 21722902, 24627126, 33508743, 20828696). Nine submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and classified this variant as uncertain significance (n=4), likely pathogenic (n=4) and pathogenic (n=1). Multiple submitters reported the variant with conflicting assessments. Based on the evidence outlined above, the variant was classified as likely pathogenic. -
Likely pathogenic, criteria provided, single submitterclinical testingMendelicsMay 04, 2022- -
not provided Pathogenic:2Uncertain:1
Likely pathogenic, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoJul 31, 2020The best available variant frequency is uninformative because it is below the disease allele frequency. Found in at least one patient with expected phenotype for this gene. Predicted to have a damaging effect on the protein. This variant is statistically more frequent in affected individuals than in the general population and/or healthy controls. -
Likely pathogenic, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesOct 19, 2022The APOB c.10679A>G; p.Tyr3560Cys variant (rs745721296), also known as Y3533C, is reported in the literature in multiple individuals with diagnosed or suspected familial hypercholesterolemia (Lima-Martínez 2017, Liyanage 2008, Medeiros 2010, Sturm 2021, Vaca 2011). This variant is also reported in ClinVar (Variation ID: 265892) and is only observed on three alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. The tyrosine at codon 3533 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.678). Based on available information, this variant is considered to be likely pathogenic. References: Lima-Martínez MM et al. Frequency and clinical and molecular aspects of familial hypercholesterolemia in an endocrinology unit in Ciudad Bolívar, Venezuela. Endocrinol Diabetes Nutr. 2017 Oct;64(8):432-439. English, Spanish. PMID: 28895539. Liyanage KE et al. High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations. Ann Clin Biochem. 2008 Mar;45(Pt 2):170-6. PMID: 18325181. Medeiros AM et al. Update of the Portuguese Familial Hypercholesterolaemia Study. Atherosclerosis. 2010 Oct;212(2):553-8. PMID: 20828696. Sturm AC et al. Limited-Variant Screening vs Comprehensive Genetic Testing for Familial Hypercholesterolemia Diagnosis. JAMA Cardiol. 2021 Aug 1;6(8):902-909. PMID: 34037665. Vaca G et al. Mutational analysis of the LDL receptor and APOB genes in Mexican individuals with autosomal dominant hypercholesterolemia. Atherosclerosis. 2011 Oct;218(2):391-6. Epub 2011 Jun 13. PMID: 21722902. -
Uncertain significance, criteria provided, single submitterclinical testingGeneDxOct 26, 2022Identified in patients with FH in published literature (Medeiros et al., 2010; Vaca et al., 2011; Lima-Martinez et al., 2017; Sturm et al., 2021; Di Taranto et al., 2021); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as p.(Y3533C); This variant is associated with the following publications: (PMID: 30710474, 18325181, 34037665, 28895539, 21722902, 34297352, 20828696) -
Hypercholesterolemia, familial, 1 Uncertain:2
Uncertain significance, criteria provided, single submitterresearchCardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo JorgeMar 01, 20160/190 non-FH alleles -
Uncertain significance, criteria provided, single submitterresearchIberoamerican FH NetworkMar 01, 2016- -
Hypercholesterolemia, autosomal dominant, type B;C4551990:Familial hypobetalipoproteinemia 1 Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 31, 2024This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 3560 of the APOB protein (p.Tyr3560Cys). This variant is present in population databases (rs745721296, gnomAD 0.009%). This missense change has been observed in individuals with hypercholesterolemia (PMID: 18325181, 20828696, 21722902, 28895539; Invitae). It has also been observed to segregate with disease in related individuals. This variant is also known as p.Tyr3533Cys. ClinVar contains an entry for this variant (Variation ID: 265892). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on APOB protein function. For these reasons, this variant has been classified as Pathogenic. -
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsMar 16, 2023The p.Y3560C variant (also known as c.10679A>G), located in coding exon 26 of the APOB gene, results from an A to G substitution at nucleotide position 10679. The tyrosine at codon 3560 is replaced by cysteine, an amino acid with highly dissimilar properties. This variant has been identified in several individuals diagnosed with familial hypercholesterolemia (Lima-Martínez MM et al. Endocrinol Diabetes Nutr, 2017 Oct;64:432-439; Vaca G et al. Atherosclerosis, 2011 Oct;218:391-6; Medeiros AM et al. Atherosclerosis, 2010 Oct;212:553-8; Liyanage KE et al. Ann Clin Biochem, 2008 Mar;45:170-6). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.35
BayesDel_addAF
Uncertain
0.045
T
BayesDel_noAF
Uncertain
0.020
CADD
Uncertain
26
DANN
Uncertain
1.0
Eigen
Uncertain
0.58
Eigen_PC
Uncertain
0.51
FATHMM_MKL
Uncertain
0.92
D
M_CAP
Benign
0.063
D
MetaRNN
Pathogenic
0.95
D
MetaSVM
Uncertain
0.085
D
MutationTaster
Benign
1.0
D
PrimateAI
Uncertain
0.51
T
PROVEAN
Pathogenic
-6.9
D
REVEL
Pathogenic
0.68
Sift
Pathogenic
0.0
D
Sift4G
Pathogenic
0.0
D
Vest4
0.83
MVP
0.89
MPC
0.30
ClinPred
0.97
D
GERP RS
4.6
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
gMVP
0.78

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs745721296; hg19: chr2-21229061; API